Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer

被引：19
|
作者：
Lou, Emil [1 ]
Vogel, Rachel I. [2 ]
Hoostal, Spencer [3 ]
Klein, Molly [4 ]
Linden, Michael A. [4 ]
Teoh, Deanna [2 ]
Geller, Melissa A. [2 ]
机构：
[1] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Obstet & Gynecol, Div Gynecol Oncol, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
来源：
JAMA ONCOLOGY | 2019年 / 5卷 / 08期
基金：
美国国家卫生研究院;
关键词：
PERCENTAGE;
D O I：
10.1001/jamaoncol.2019.1943
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This study assesses tumor-stroma proportion and compares this finding with the development of resistance to platinum-based chemotherapy in women newly diagnosed with ovarian carcinoma.
引用
收藏
页码：1222 / 1224
页数：3
相关论文
共 50 条
  • [31] ERCC1 Expression as a Predictor of Resistance to Platinum-based Chemotherapy in Primary Ovarian Cancer
    Muallem, Mustafa Zelal
    Braicu, Ioana
    Nassir, Mani
    Richter, Rolf
    Sehouli, Jalid
    Arsenic, Ruza
    ANTICANCER RESEARCH, 2014, 34 (1A) : 393 - 399
  • [32] Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
    Hansen, Torben Frostrup
    Kjaer-Frifeldt, Sanne
    Lindebjerg, Jan
    Rafaelsen, Soren Rafael
    Jensen, Lars Henrik
    Jakobsen, Anders
    Sorensen, Flemming Brandt
    ACTA ONCOLOGICA, 2018, 57 (04) : 528 - 533
  • [33] NEOADJUVANT CHEMOTHERAPY MAY IMPAIR RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY FOR OVARIAN CANCER PATIENTS
    Ekmann-Gade, A. W.
    Hogdall, C.
    Peen, U. B. S.
    Engelholm, S. A.
    Fago-Olsen, C. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 675 - 676
  • [34] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Jianli Chen
    Nashwa Emara
    Charalambos Solomides
    Hemant Parekh
    Henry Simpkins
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1103 - 1111
  • [35] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Chen, Jianli
    Emara, Nashwa
    Solomides, Charalambos
    Parekh, Hemant
    Simpkins, Henry
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1103 - 1111
  • [36] Potential Transcriptomic Biomarkers for Predicting Platinum-based Chemotherapy Resistance in Patients With High-grade Serous Ovarian Cancer
    Cocchi, Sara
    Lopacinska-Jorgensen, Joanna
    Hogdall, Estrid, V
    ANTICANCER RESEARCH, 2024, 44 (11) : 4691 - 4707
  • [37] Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients
    Eitan, Ram
    Kushnir, Michal
    Lithwick-Yanai, Gila
    Ben David, Miriam
    Hoshen, Moshe
    Glezerman, Marek
    Hod, Moshe
    Sabah, Gad
    Rosenwald, Shai
    Levavi, Hanoch
    GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 253 - 259
  • [38] Uncoupling tumor-stroma interactions in breast cancer patients
    Sourbier, Carole
    Neckers, Len
    SEMINARS IN ONCOLOGY, 2017, 44 (03) : 235 - 236
  • [39] Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer
    Milczek, Tomasz
    Klasa-Mazurkiewicz, Dagmara
    Emerich, Janusz
    Kobierski, Juliusz
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2009, 88 (04) : 463 - 467
  • [40] Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy
    Geens, Margot
    Stappers, Sofie
    Konings, Heleen
    De Winter, Benedicte Y.
    Specenier, Pol
    Van Meerbeeck, Jan P.
    Verpooten, Gert A.
    Abrams, Steven
    Janssens, Annelies
    Peeters, Marc
    Van de Heyning, Paul
    Vanderveken, Olivier M.
    Ledeganck, Kristien J.
    PLOS ONE, 2021, 16 (06):
12345